Literature DB >> 77945

Prevention of iron loading in transfusion-dependent thalassaemia.

M J Pippard, E A Letsky, S T Callender, D J Weatherall.   

Abstract

Urinary iron excretion after single intramuscular (i.m.) bolus injections or 12 h subcutaneous (s.c.) infusions of desferrioxamine (D.F.) was determined in sixteen homozygous beta-thalassaemia patients whose ages ranged from 10 months to 23 years. At all ages the s.c. infusions resulted in greater iron loss than identical i.m. doses. With doses of 0.5-1 g of D.F. as s.c. infusions eight out of nine children aged less than 6 years with a total transfusion iron load of less than 10 g excreted sufficient iron to achieve iron balance. These results suggest that iron loading in transfusion-dependent thalassaemics may be preventable by the use of an appropriate chelation regimen started early in life.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 77945     DOI: 10.1016/s0140-6736(78)90968-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  12 in total

Review 1.  Current concepts in the management of thalassemia.

Authors:  R S Festa
Journal:  Indian J Pediatr       Date:  1987 May-Jun       Impact factor: 1.967

2.  Intensive iron-chelation in thalassaemia.

Authors: 
Journal:  Br Med J       Date:  1978-09-16

3.  Survival and desferrioxamine in thalassaemia major.

Authors:  B Modell; E A Letsky; D M Flynn; R Peto; D J Weatherall
Journal:  Br Med J (Clin Res Ed)       Date:  1982-04-10

4.  Primary hypothyroidism and the low T3 syndrome in thalassaemia major.

Authors:  A R Sabato; V de Sanctis; G Atti; L Capra; B Bagni; C Vullo
Journal:  Arch Dis Child       Date:  1983-02       Impact factor: 3.791

5.  Effect of introducing antenatal diagnosis on reproductive behaviour of families at risk for thalassaemia major.

Authors:  B Modell; R H Ward; D V Fairweather
Journal:  Br Med J       Date:  1980-06-07

6.  Early iron overload in beta-thalassaemia major: when to start chelation therapy?

Authors:  S Fargion; M T Taddei; V Gabutti; A Piga; A Di Palma; L Capra; G Fontanelli; A Avanzini
Journal:  Arch Dis Child       Date:  1982-12       Impact factor: 3.791

7.  Metabolism and pharmacokinetics of 1-(2'-hydroxy-ethyl)- and 1-(3'-hydroxypropyl)-2-ethyl-3-hydroxypyridin-4-ones in the rat.

Authors:  S Singh; R Choudhury; R O Epemolu; R C Hider
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Jan-Mar       Impact factor: 2.441

Review 8.  Management of the thalassemias.

Authors:  Nancy F Olivieri; Gary M Brittenham
Journal:  Cold Spring Harb Perspect Med       Date:  2013-06-01       Impact factor: 6.915

9.  Studies of variations of subcutaneously infused desferrioxamine and iron movements in thalassaemia children.

Authors:  E A Llados i Vallory; R Girot; G Lenoir; M Payet; P Houze; R Bourdon
Journal:  Eur J Pediatr       Date:  1989-04       Impact factor: 3.183

10.  Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of deferoxamine.

Authors:  S Merali; K Chin; R W Grady; L Weissberger; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.